Pathstone Family Office’s Kite Pharma, Inc. KITE Stock Holding History

Pathstone Family Office’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,500	Closed	-$156K	–	383
2017 Q2	$156K	Buy	1,500 +750	+100%	+$61.2K	0.07%	120
2017 Q1	$59K	Buy	+750	New	+$46.4K	0.03%	169
2016 Q4	–	Sell	-422	Closed	-$74K	–	233
2016 Q3	$74K	Hold	422	–	–	0.08%	49
2016 Q2	$21K	Buy	422 +100	+31%	+$4.91K	0.02%	89
2016 Q1	$15K	Buy	+322	New	+$15.6K	0.03%	88

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Pathstone Family Office's KITE Position: Q3 2017 in Review

Pathstone Family Office sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 1,500 shares — an estimated $156K sold.

Pathstone Family Office first reported a position in KITE in Q1 2016 and held it in 5 quarters. The position peaked at $156K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Pathstone Family Office reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Pathstone Family Office sold 1,500 Kite Pharma, Inc. shares in Q3 2017, an estimated $156K.
Pathstone Family Office first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 5 quarters.
Pathstone Family Office's Kite Pharma, Inc. position peaked at $156K in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Pathstone Family Office's 13F filing for Q3 2017, filed 14 Nov 2017.